Not Yet RecruitingNot Applicable

Prevalence of EILO Among Children With Asthma

Netherlands200 participantsStarted 2024-08-01

Plain-language summary

The goal of this cross-sectional study is to investigate the prevalence of Exercise Induced Laryngeal Obstruction (EILO) in children with asthma. The hypothesis is that the prevalence will be around 15%, which is higher than the prevalence of 5-8% among the general adolescent population. This is based on the increased prevalence of EILO among adult asthmatics. Participants who are referred for an Exercise Challenge Test will perform an additional Continuous Laryngoscopy during Exercise Test with expiratory FEV1 curves, and fill in the Borg scale for dyspnea, Asthma Control Test, EILODI questionnaire and DISCO-RC questionnaire.

Who can participate

Age range12 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 12 to 18 years * Paediatrician diagnosed asthma confirmed with at least one of the following during the last two years: Positive ECT (post-exercise fall in FEV1 \> 10%) / Positive methacholine test (PC20 value of ≤8 mg/mL) / Bronchodilator reversibility (increase in FEV1 ≥12% and/or ≥200 mL following inhalation of 200-400 μg short-acting β2-agonists) Exclusion Criteria: * Other severe cardiopulmonary disease * Inability to perform ECT or CLE test * Inability to perform technically acceptable spirometry * Asthma exacerbation or respiratory tract infection in the last 2 weeks * Short-acting β2-agonists or long-acting β2-agonists use less than respectively 8 and 24 hours before the ECT or CLE test * Oral corticosteroid use in the 4 weeks before the ECT or CLE test

What they're measuring

Prevalence of EILO

Timeframe: During CLE test. Measured in period until 200 participants are enrolled, expected to be 2 years

Trial details

NCT IDNCT06480084

SponsorMedisch Spectrum Twente

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-01

Contact for this trial

Vera Hengeveld, MD

+31 53 487 23 10 vera.hengeveld@mst.nl